HrHPV in the population research on cervical cancer.

Completed

Conditions: Cervical intraepithelial neoplasia and cervical cancer. Due to the low prevalence of invasive cervical cancer in the Netherlands, and the aim of cervical screening to prevent the occurrence of and death caused by to cervical cancer, we evaluate the prevalence of a surrogate marker for cervical cancer incidence, namely the immediate precursor lesion of cervical cancer cervical intra-epithelial neoplasia grade 3.

Registration Number: NL-OMON28695

Lead Sponsor: - Department of Pathology, VU University Medical Center- Department of Pathology, Spaarne Ziekenhuis, Hoofddorp- Leiden Cytology and Pathology Laboratory, Leiden- Stichting PA Laboratorium Kennemerland, Haarlem

Brief Summary: NWJ Bulkmans, L Rozendaal, PJF Snijders, FJ Voorhorst, AJP Boeke, GRJ Zandwijken, FJ van Kemenade, RHM Verheijen, K v Groningen, ME Boon, HJF Keuning, M van Ballegooijen, AJC van den Brule, CJLM Meijer. POBASCAM, a population-based randomised controlled trial for implementation of high-risk HPV testing in cervical screening; Design, methods and baseline data of 44,102 women. International Journal of Cancer 2004; 110 (1): 94-101. DOI 10.1002/ijc.20076<br> - NWJ Bulkmans, MCG Bleeker, J Berkhof, FJ Voorhorst, PJF Snijders, CJLM Meijer. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. International Journal of Cancer 2005; 117 (2): 177-181. DOI: 10.1002/ijc.21210

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 44102

Inclusion Criteria

1. Women invited for the cervical cancer screening program (ages 30-60 years);

2. Residing in either the region covered by district health authority Amstelland-de Meerlanden and Zuid-Kennemerland.

Exclusion Criteria

1. Not called for screening, i.e., ages under 30 years, or over 60 years;

2. Follow-up of previous non-normal cytology within the current screening round of the program, i.e., abnormal cytology or CIN lesions less than 2 years before inclusion;